The present disclosure provides compositions, kits, and methods to protect organs by inducing acquired cytoresistance without causing injury to the organ. The compositions, kits, and methods utilize Me-porphryin complexs, heme proteins, iron containing molecules, and/or vitamin B12 and, optionally, agents that impact heme protein metabolism.

The present invention generally relates to treatment of iron-related conditions with iron carbohydrate complexes. One aspect of the invention is a method of treatment of iron-related conditions with a single unit dosage of at least about 0.6 grams of elemental iron via an iron carbohydrate complex. The method generally employs iron carbohydrate complexes with nearly neutral pH, physiological osmolarity, and stable and non-immunogenic carbohydrate components so as to rapidly administer high single unit doses of iron intravenously to patients in need thereof.

The present invention generally relates to treatment of iron-related conditions with iron carbohydrate complexes. One aspect of the invention is a method of treatment of iron-related conditions with a single unit dosage of at least about 0.6 grams of elemental iron via an iron carbohydrate complex. The method generally employs iron carbohydrate complexes with nearly neutral pH, physiological osmolarity, and stable and non-immunogenic carbohydrate components so as to rapidly administer high single unit doses of iron intravenously to patients in need thereof.

The present invention generally relates to treatment of iron-related conditions with iron carbohydrate complexes. One aspect of the invention is a method of treatment of iron-related conditions with a single unit dosage of at least about 0.6 grams of elemental iron via an iron carbohydrate complex. The method generally employs iron carbohydrate complexes with nearly neutral pH, physiological osmolarity, and stable and non-immunogenic carbohydrate components so as to rapidly administer high single unit doses of iron intravenously to patients in need thereof.

The present invention generally relates to treatment of iron-related conditions with iron carbohydrate complexes. One aspect of the invention is a method of treatment of iron-related conditions with a single unit dosage of at least about 0.6 grams of elemental iron via an iron carbohydrate complex. The method generally employs iron carbohydrate complexes with nearly neutral pH, physiological osmolarity, and stable and non-immunogenic carbohydrate components so as to rapidly administer high single unit doses of iron intravenously to patients in need thereof.

Use of (pyrophosphato)platinum(II) or (pyrophosphato)platinum(IV) complexes (phosphaplatin compounds), especially (R,R)1,2-cyclohexanediamine-(dihydrogen pyrophosphato)platinum(II) (or PT-112), as therapeutic agents for treatment of bone and blood cancers, or cancers that metastasize to bones, and methods thereof, are disclosed.

The present invention relates to a method for maintaining normoglycemia in a mammal in need thereof, preferably a critically ill patient suffering from acute stress, and to a method for preventing or limiting renal ischemia-reperfusion (I/R) in a mammal, preferably in a critically ill patient suffering from acute stress.

Described herein is a LIN28-independent role of TUTases in oncogenesis. Provided herein are compositions and methods for treating cancer via inhibition of TUTases. TUTase depletion also sensitizes the cells to disruptions in RNA metabolism and/or protein metabolism. Thus, further provided herein are strategies of combination therapy, combining TUTase inhibitors, agents that disrupt RNA metabolism, and agents that disrupt protein metabolism, to treat cancer.

Described herein is a LIN28-independent role of TUTases in oncogenesis. Provided herein are compositions and methods for treating cancer via inhibition of TUTases. TUTase depletion also sensitizes the cells to disruptions in RNA metabolism and/or protein metabolism. Thus, further provided herein are strategies of combination therapy, combining TUTase inhibitors, agents that disrupt RNA metabolism, and agents that disrupt protein metabolism, to treat cancer.

Disclosed herein, inter alia, are prodrug compositions and methods of using the same for treatment and detection of disease. Specifically, disclosed herein is a compound of formula (I) having spiro-fused 1,2,4-trioxolane and piperidine rings, namely, 1,2,4-trioxa-8-azaspiro[4.5]decane. Also disclosed is a pharmaceutical composition containing the compound and a pharmaceutically acceptable carrier.

##STR00001##